BofA raised the firm’s price target on GoodRx (GDRX) to $4.75 from $4.25 and keeps an Underperform rating on the shares. GoodRx introduced 2025 guidance that was better than the firm expected given the amount of marketplace changes beginning to take place this year, but BofA remains cautious on the growth trajectory in 2025 and beyond, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: